Background and aims: Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasms that arise in the gastrointestinal tract.They constitute about 0.1-3% of all GI tumours. Annual incidence is 1.2 per 105 individuals. Surgery remains the main stay of treatment. The use of adjuvant TKI Imatinib mesylate for 3 years reduce the frequency of disease recurrencefollowing complete resection.Five year survival for all stages combined is upto 83%.Here we present a five year retrospective data on the clinicopathological features and outcomes of GIST from a tertiary cancer care centre in south India.